ADCIRCA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Adcirca, and what generic alternatives are available?
Adcirca is a drug marketed by Eli Lilly Co and is included in one NDA.
The generic ingredient in ADCIRCA is tadalafil. There are twenty-five drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the tadalafil profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Adcirca
A generic version of ADCIRCA was approved as tadalafil by TEVA PHARMS USA on May 22nd, 2018.
Summary for ADCIRCA
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 98 |
Clinical Trials: | 23 |
Patent Applications: | 6,090 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for ADCIRCA |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ADCIRCA |
What excipients (inactive ingredients) are in ADCIRCA? | ADCIRCA excipients list |
DailyMed Link: | ADCIRCA at DailyMed |


Recent Clinical Trials for ADCIRCA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
The Curtis L. Brown Glioblastoma Research Fund | Phase 1 |
Washington University School of Medicine | Phase 1 |
Shanghai Institute of Materia Medica, Chinese Academy of Sciences | Phase 2 |
Pharmacology for ADCIRCA
Drug Class | Phosphodiesterase 5 Inhibitor |
Mechanism of Action | Phosphodiesterase 5 Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for ADCIRCA
US Patents and Regulatory Information for ADCIRCA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly Co | ADCIRCA | tadalafil | TABLET;ORAL | 022332-001 | May 22, 2009 | AB2 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ADCIRCA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Eli Lilly Co | ADCIRCA | tadalafil | TABLET;ORAL | 022332-001 | May 22, 2009 | See Plans and Pricing | See Plans and Pricing |
Eli Lilly Co | ADCIRCA | tadalafil | TABLET;ORAL | 022332-001 | May 22, 2009 | See Plans and Pricing | See Plans and Pricing |
Eli Lilly Co | ADCIRCA | tadalafil | TABLET;ORAL | 022332-001 | May 22, 2009 | See Plans and Pricing | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ADCIRCA
See the table below for patents covering ADCIRCA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Hungary | 222494 | Pirazino-pirido-indol-származékok, előállításuk és gyógyszerkénti alkalmazásuk, ezeket tartalmazó gyógyszerkészítmények, valamint intermedierek (PYRAZINO-PYRIDO-INDOLE-DERIVATIVES, PROCESS OF PREPARATION AND USE AS MEDICAMENT, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND INTERMEDIATES) | See Plans and Pricing |
Norway | 20020531 | See Plans and Pricing | |
Iceland | 4252 | See Plans and Pricing | |
Hungary | 0202781 | See Plans and Pricing | |
Algeria | 3179 | Compositions pharmaceutiques à base de beta-carboline. | See Plans and Pricing |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ADCIRCA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2101777 | CA 2016 00024 | Denmark | See Plans and Pricing | PRODUCT NAME: AMBRISENTAN USED IN COMBINATION TREATMENT WITH TADALAFIL; REG. NO/DATE: EU/1/08/451 (001-004) 20151125 |
0740668 | PA2003001,C0740668 | Lithuania | See Plans and Pricing | PRODUCT NAME: TADALAFILUM ((6R,12AR)-2,3,6,7,12,12A-HEKSAHIDRO-2-METIL-6-(3,4-METILENDIOKSIFENIL)-PIRAZINO(2',1':6,1)PIRIDO(3,4-B)INDOL-1,4-DIONAS); REGISTRATION NO/DATE: 03/8034/3, 03/8035/3 20030328 |
0740668 | 03C0017 | France | See Plans and Pricing | PRODUCT NAME: TADALAFIL; REGISTRATION NO/DATE: EU/1/02/237/001-004 20021112 |
0740668 | C00740668/01 | Switzerland | See Plans and Pricing | PRODUCT NAME: TADALAFILUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 56018 04.05.2004 |
0740668 | 91017 | Luxembourg | See Plans and Pricing | |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |